{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T19:13:23Z","timestamp":1723144403411},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,10,26]],"date-time":"2010-10-26T00:00:00Z","timestamp":1288051200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s10549-010-1216-1","type":"journal-article","created":{"date-parts":[[2010,10,25]],"date-time":"2010-10-25T04:19:26Z","timestamp":1287980366000},"page":"511-520","source":"Crossref","is-referenced-by-count":9,"title":["Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer"],"prefix":"10.1007","volume":"127","author":[{"given":"Suja S.","family":"Rajan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary H.","family":"Lyman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally C.","family":"Stearns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,26]]},"reference":[{"key":"1216_CR1","unstructured":"American Cancer Society (2009) Breast cancer facts and figures\u00a02009\u20132010. ACS, Atlanta"},{"key":"1216_CR2","doi-asserted-by":"crossref","unstructured":"Earle CC, Nattinger AB, Potosky AL et al (2002) Identifying cancer relapse using SEER-Medicare Data. Med Care 40(8 Suppl):IV-75\u201381","DOI":"10.1097\/00005650-200208001-00011"},{"key":"1216_CR3","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365:1687\u20131717","journal-title":"Lancet"},{"key":"1216_CR4","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","volume":"352","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"1998","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352:930\u2013942","journal-title":"Lancet"},{"key":"1216_CR5","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJM198812293192601","volume":"319","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"1992","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (1992) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28,896 women. N Engl J Med 319:1681\u20131692","journal-title":"N Engl J Med"},{"issue":"1\u201315","key":"1216_CR6","first-page":"71","volume":"339","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"1988","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (1988) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339(1\u201315):71\u201385","journal-title":"Lancet"},{"key":"1216_CR7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3322\/canjclin.49.3.159","volume":"49","author":"B Fisher","year":"1999","unstructured":"Fisher B (1999) Highlights from recent national surgical adjuvant breast and bowel project studies in the treatment and prevention of breast cancer. CA Cancer J Clin 49:159\u2013177","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"1216_CR8","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1200\/JCO.1990.8.6.1005","volume":"8","author":"B Fisher","year":"1990","unstructured":"Fisher B, Redmond C, Legault PS et al (1990) Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8(6):1005\u20131018","journal-title":"J Clin Oncol"},{"key":"1216_CR9","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM199810013391407","volume":"339","author":"GN Hortobagyi","year":"1998","unstructured":"Hortobagyi GN (1998) Treatment of breast cancer. N Engl J Med 339:974\u2013984","journal-title":"N Engl J Med"},{"issue":"6","key":"1216_CR10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/107327489600300605","volume":"3","author":"J Webster","year":"1996","unstructured":"Webster J, Lyman G (1996) Use of G-CSF to sustain dose intensity in breast cancer patients receiving adjuvant chemotherapy: a pilot study. Cancer Control 3(6):519\u2013523","journal-title":"Cancer Control"},{"key":"1216_CR11","volume-title":"Toxicity of chemotherapy","author":"MC Perry","year":"1984","unstructured":"Perry MC, Yarbro JW (1984) Toxicity of chemotherapy. Gruene & Stratton, Orlando"},{"key":"1216_CR12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10549-006-9254-4","volume":"100","author":"M Shayne","year":"2006","unstructured":"Shayne M, Crawford J, Dale DC et al (2006) Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 100:255\u2013262","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1216_CR13","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00002820-200607000-00002","volume":"29","author":"J Ziegler","year":"2006","unstructured":"Ziegler J, Citron M (2006) Dose-dense adjuvant chemotherapy for breast cancer. Cancer Nurs 29(4):266\u2013272","journal-title":"Cancer Nurs"},{"issue":"5","key":"1216_CR14","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/107327480301000507","volume":"10","author":"EA Chrischilles","year":"2003","unstructured":"Chrischilles EA, Link KB, Scott SD et al (2003) Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate grade non-Hodgkin\u2019s lymphoma. Cancer Control 10(5):396\u2013403","journal-title":"Cancer Control"},{"issue":"2","key":"1216_CR15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1524-4733.2007.00242.x","volume":"11","author":"A Eldar-Lissai","year":"2007","unstructured":"Eldar-Lissai A, Cosler LE, Culakova E et al (2007) Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 11(2):172\u2013179","journal-title":"Value Health"},{"key":"1216_CR16","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"N Kuderer","year":"2006","unstructured":"Kuderer N, Dale D, Crawford J, Lyman GH (2006) The morbidity, mortality and cost of febrile neutropenia in cancer patients. Cancer 106:2258\u20132266","journal-title":"Cancer"},{"issue":"6","key":"1216_CR17","first-page":"488","volume":"85","author":"GH Lyman","year":"1993","unstructured":"Lyman GH, Lyman CG, Sanderson RA, Balducci L (1993) Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. N Engl J Med 85(6):488\u2013493","journal-title":"N Engl J Med"},{"issue":"12","key":"1216_CR18","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0959-8049(98)00222-6","volume":"34","author":"GH Lyman","year":"1998","unstructured":"Lyman GH, Kuderer NM, Greene J (1998) The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 34(12):1857\u20131864","journal-title":"Eur J Cancer"},{"key":"1216_CR19","unstructured":"Weycker D, Malin J, Glass A, Oster G (2007) Economic burden of chemotherapy-related febrile neutropenia. J Supp Oncol 5(4):Suppl 2:44\u201345"},{"issue":"6","key":"1216_CR20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/107327480301000607","volume":"10","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Kuderer N, Agboola O et al (2003) Evidence-based use of colony-stimulating factors in elderly cancer patients. Cancer Control 10(6):487\u2013499","journal-title":"Cancer Control"},{"issue":"21","key":"1216_CR21","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NN Kuderer","year":"2007","unstructured":"Kuderer NN, Dale DC, Crawford J et al (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25(21):3158\u20133167","journal-title":"J Clin Oncol"},{"key":"1216_CR22","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1200\/JCO.2003.05.002","volume":"21","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Dale DC, Crawford J (2003) Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21:4524\u20134531","journal-title":"J Clin Oncol"},{"key":"1216_CR23","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1188\/05.ONF.757-764","volume":"32","author":"C Lenhart","year":"2005","unstructured":"Lenhart C (2005) Relative dose intensity: improving cancer treatment and outcomes. Oncol Nurs Forum 32:757\u2013764","journal-title":"Oncol Nurs Forum"},{"key":"1216_CR24","unstructured":"Chrischilles EA, Rubenstein LM, Voelker MD, Wright et al (2003) Granulocyte colony-stimulating factor use during first course chemotherapy for non-Hodgkin\u2019s lymphoma: National SEER-Medicare Study. Session Type: Poster Session 929-I"},{"issue":"34","key":"1216_CR25","doi-asserted-by":"crossref","first-page":"8620","DOI":"10.1200\/JCO.2005.02.6252","volume":"23","author":"XL Du","year":"2005","unstructured":"Du XL, Lairson DR, Begley E et al (2005) Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort. J Clin Oncol 23(34):8620\u20138628","journal-title":"J Clin Oncol"},{"issue":"5","key":"1216_CR26","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10552-005-0502-4","volume":"17","author":"S Chen-Hardee","year":"2006","unstructured":"Chen-Hardee S, Chrischilles EA, Voelker MD (2006) Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin\u2019s lymphoma (United States). Cancer Causes Control 17(5):647\u2013654","journal-title":"Cancer Causes Control"},{"issue":"3","key":"1216_CR27","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/107327480200900303","volume":"9","author":"EA Chrischilles","year":"2002","unstructured":"Chrischilles EA, Delgado DJ, Stolshek BS (2002) Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin\u2019s lymphoma. Cancer Control 9(3):203\u2013211","journal-title":"Cancer Control"},{"key":"1216_CR28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1532-5415.1984.tb02020.x","volume":"32","author":"JO Armitage","year":"1984","unstructured":"Armitage JO, Potter JF (1984) Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc 32:269\u2013273","journal-title":"J Am Geriatr Soc"},{"key":"1216_CR29","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1200\/JCO.1998.16.6.2065","volume":"16","author":"H Gomez","year":"1998","unstructured":"Gomez H, Hidalgo M, Casanova L et al (1998) Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin\u2019s lymphoma: results of a multivariate analysis. J Clin Oncol 16:2065\u20132069","journal-title":"J Clin Oncol"},{"issue":"7","key":"1216_CR30","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/cncr.22939","volume":"110","author":"M Shayne","year":"2007","unstructured":"Shayne M, Culakova E, Poniewierski MS et al (2007) Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer 110(7):1611\u20131620","journal-title":"Cancer"},{"key":"1216_CR31","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2005.04.3281","volume":"24","author":"JN Timmer-Bonte","year":"2006","unstructured":"Timmer-Bonte JN, Adang EM, Smit HJ (2006) Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in patients with small-cell lung cancer. J Clin Oncol 24:2991\u20132997","journal-title":"J Clin Oncol"},{"issue":"1","key":"1216_CR32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.critrevonc.2007.01.008","volume":"63","author":"C Gridelli","year":"2007","unstructured":"Gridelli C, Matti A, Sandro B, Giordano B et al (2007) Role of colony stimulating factors (CSFs) in solid tumors: results of an expert panel. Crit Rev Oncol Hematol 63(1):53\u201364","journal-title":"Crit Rev Oncol Hematol"},{"key":"1216_CR33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00520-001-0312-5","volume":"10","author":"T Berghmans","year":"2002","unstructured":"Berghmans T, Paesmans M, Lafitte JJ et al (2002) Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 10:181\u2013188","journal-title":"Support Care Cancer"},{"key":"1216_CR34","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1200\/JCO.2005.05.645","volume":"23","author":"O Clark","year":"2005","unstructured":"Clark O, Lyman GH, Castro AA et al (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23:4198\u20134214","journal-title":"J Clin Oncol"},{"issue":"25","key":"1216_CR35","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1056\/NEJM199706193362502","volume":"336","author":"LC Hartmann","year":"1997","unstructured":"Hartmann LC, Tschetter LK, Habermann TM et al (1997) Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 336(25):1776\u20131780","journal-title":"N Engl J Med"},{"issue":"1","key":"1216_CR36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jnci\/93.1.31","volume":"91","author":"R Garc\u00eda-Carbonero","year":"2001","unstructured":"Garc\u00eda-Carbonero R, Mayordomo JI, Tornamira MV et al (2001) Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 91(1):31\u201338","journal-title":"J Natl Cancer Inst"},{"key":"1216_CR37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.critrevonc.2004.01.001","volume":"50","author":"GH Lyman","year":"2004","unstructured":"Lyman GH, Kuderer NM (2004) The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 50:129\u2013146","journal-title":"Crit Rev Oncol Hematol"},{"key":"1216_CR38","unstructured":"Package insert. Neupogen (Filgrastim). Amgen. www.neupogen.com . Accessed 26 March 2009"},{"key":"1216_CR39","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1345\/aph.1G516","volume":"40","author":"D Weycker","year":"2006","unstructured":"Weycker D, Hackett J, Edelsberg JS et al (2006) Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40:402\u2013407","journal-title":"Ann Pharmacother"},{"key":"1216_CR40","doi-asserted-by":"crossref","unstructured":"Weycker D, Hackett J, Edelsberg JS et al (2004) Duration of G-CSF therapy and risk of hospitalization for neutropenia or infection. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22(14S) (July 15 Supplement): 6731","DOI":"10.1200\/jco.2004.22.90140.6731"},{"issue":"Suppl 2","key":"1216_CR41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.18553\/jmcp.2003.9.s2.15","volume":"9","author":"SD Scott","year":"2003","unstructured":"Scott SD, Chrischilles EA, Link BK et al (2003) Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin\u2019s lymphoma treated with chemotherapy. J Manag Care Pharm 9(Suppl 2):15\u201321","journal-title":"J Manag Care Pharm"},{"key":"1216_CR42","doi-asserted-by":"crossref","unstructured":"Warren JL, Klabunde CN, Schrag Deborah et al (2002) Overview of the SEER-Medicare Data: content, research applications, and generalizability to the United States Elderly Population. Med Care 40(8): IV-3\u2013IV-18","DOI":"10.1097\/00005650-200208001-00002"},{"issue":"26","key":"1216_CR43","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1056\/NEJM200106283442607","volume":"344","author":"CL Shapiro","year":"2001","unstructured":"Shapiro CL, Recht A (2001) Side effects of adjuvant treatment of breast cancer. N Engl J Med 344(26):1997\u20132008","journal-title":"N Engl J Med"},{"key":"1216_CR44","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1023\/A:1008271804151","volume":"8","author":"J Crawford","year":"1997","unstructured":"Crawford J, Kreisman H, Garewal H et al (1997) The impact of filgrastim schedule variation on hematopoietic recovery post-chemotherapy. Ann Oncol 8:1117\u20131124","journal-title":"Ann Oncol"},{"issue":"Suppl 11","key":"1216_CR45","first-page":"8","volume":"17","author":"GH Lyman","year":"2003","unstructured":"Lyman GH (2003) Risk assessment in oncology clinical practice: from risk factors to risk models. Oncology 17(Suppl 11):8\u201313","journal-title":"Oncology"},{"key":"1216_CR46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/978-1-59259-747-5_21","volume-title":"Hematopoietic growth factors in oncology: basic science and clinical therapeutics","author":"GH Lyman","year":"2004","unstructured":"Lyman GH, Kuderer NM (2004) Economics of hematopoietic growth factors. In: Morstyn G, Foote M, Lieschke GJ (eds) Hematopoietic growth factors in oncology: basic science and clinical therapeutics. Humana Press Inc., Totowa, pp 409\u2013443"},{"key":"1216_CR47","unstructured":"Levinson DR (2009) Medicare part B chemotherapy administration: payment and policy. Department of Health and Human Services, Washington"},{"issue":"1","key":"1216_CR48","first-page":"5","volume":"4","author":"M Olsen","year":"2006","unstructured":"Olsen M (2006) Medicare reimbursement issues in supportive care. Cancer Ther Supportive Care 4(1):5\u20138","journal-title":"Cancer Ther Supportive Care"},{"key":"1216_CR49","unstructured":"Amgen (2001) Guide to coverage and reimbursement for Neupogen vial and Neupogen singleject prefilled syringe: reimbursement information for Neupogen. Amgen Inc., Thousand Oaks"},{"issue":"19","key":"1216_CR50","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH et al (2006) Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24(19):3187\u20133205","journal-title":"J Clin Oncol"},{"key":"1216_CR51","doi-asserted-by":"crossref","unstructured":"Rolston KV (2004) The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments. Clin Infect Dis 39(Suppl 1):S44\u2013S48","DOI":"10.1086\/383053"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-1216-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-010-1216-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-1216-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T16:05:29Z","timestamp":1636733129000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-010-1216-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,26]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["1216"],"URL":"https:\/\/doi.org\/10.1007\/s10549-010-1216-1","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,26]]}}}